Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 3, 2013, Pages 509-519

  Zhang, Man ^a   Meng, Qian ^a   Lei, Ting ^a   Zhang, Min ^a   Zhao, Jin ^a   Zhao, Xu Hong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Annexin A2; Bladder cancer; Multidrug resistance; Nucleophosmin

Indexed keywords

DOXORUBICIN; LIPOCORTIN 2; NUCLEOPHOSMIN; PROTEOME; ANTINEOPLASTIC ANTIBIOTIC; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN ADM; CELL STRAIN PUMC 91; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; BLADDER TUMOR; CARCINOMA; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY; PROTEOMICS; TUMOR CELL LINE; VALIDATION STUDY;

AMINO ACID SEQUENCE; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; URINARY BLADDER NEOPLASMS; VALIDATION STUDIES AS TOPIC;

MLCS; MLOWN;

EID: 84876305991     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1350-8     Document Type: Article

References (50)

1. Baguley BC (2010) Multi-drug resistance in cancer. Methods Mol Biol 596:1-9
2. Borer RA, Lehner CF, Eppenberger HM et al (1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56:379-390
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
4. Cole SP, Pinkoski MJ, Bhardwaj G et al (1992) Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 65(4):498-502
5. Colombo E, Marine JC, Danovi D et al (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4:529-533
6. Dhar SK, Lynn BC, Daosukho C et al (2004) Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem 279:28209-28219
7. Emoto K, Sawada H, Yamada Y et al (2001a) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21:1339-1345
8. Emoto K, Yamada Y, Sawada H et al (2001b) Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92:1419-1426
9. Falini B, Mecucci C, Tiacci E et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266
10. Flood EC, Hajjar KA (2011) The annexin A2 system and vascular homeostasis. Vasc Pharmacol 54:59-67
11. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331-371
12. Gingrich JR (2011) Chemohyperthermia for bladder cancer - clinically effective? Nat Rev Urol 8:414-416
13. Hasegawa S, Abe T, Naito S et al (1995) Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71:907-913
14. Hayes MJ, Moss SE (2004) Annexins and disease. Biochem Biophys Res Commun 322:1166-1170
15. Herrera JE, Savkur R, Olson MO (1995) The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res 23:3974-3979
16. Hong L, Piao Y, Han Y et al (2005) Zinc ribbon domain containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther 4:1936-1942
17. Hsu CY, Yung BY (2000) Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int J Cancer 88:392-400
18. Hu J, Lin M, Liu T et al (2011) DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia. Leukemia Res 35:1087-1109
19. Ichimi T, Enokida H, Okuno Y et al (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125:345-352
20. Kikuta K, Tochigi N, Shimoda T et al (2009) Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res 15:2885-2894
21. Korgaonkar C, Hagen J, Tompkins V et al (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25:1258-1271
22. Liang Y, McDonnell S, Clynes M (2002) Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets 2(3):257-277
23. Lim MJ, Wang XW (2006) Nucleophosmin and human cancer. Cancer Detect Prev 30:481-490
24. Lin CY, Liang YC, Yung Benjamin YM (2006) Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-κB, E2F1 and pRB. Cell Signal 18:2041-2048
25. Liu JW, Shen JJ, Tanzillo-Swarts A et al (2003) Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 22:1475-1485
26. Liu X, Liu ZX, Jang SW et al (2007) Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. PNAS 104(23):9679-9684
27. Nakagawa M, Emoto A, Nasu N et al (1997) Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 157:1260-1265
28. Nozawa Y, Van Belzen N, Vander Made AC et al (1996) Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 178:48-52
29. Pastorelli R, Carpi D, Campagna R et al (2007) Proteome characterization of a human urothelial cell line resistant to the bladder carcinogen 4-aminobiphenyl. Proteome Sci 5:6-14
30. Pianta A, Puppin C, Deganuto M et al (2010) Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun 397:499-504
31. Schulz DM, llner CB, Thomas G et al (2009) Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 8:3430-3438
32. Sharma MR, Koltowski L, Ownbey RT et al (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146-156
33. Subong EN, Shue MJ, Epstein JI et al (1999) Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 39:298-304
34. Szebeni A, Olson MO (1999) Nucleolar protein B23 has molecular chaperone activities. Protein Sci 8:905-912
35. Tada Y, Wada M, Kuroiwa K et al (2000) MDR1 overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6:4618-4627
36. Tanaka M, Sasaki H, Kino I et al (1992) Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res 52:3372-3377
37. Tokuyama Y, Horn HF, Kawamura K et al (2001) Specific phosphorylation of nucleophosmin on Thr(199) by cyclin dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem 276:21529-21537
38. Tsui KH, Cheng AJ, Chang PL et al (2004) Association of nucleophosmin/b23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 64:839-844
39. Tusi KH, Juang HH, Lee TH et al (2008) Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin 29(3):364-370
40. Verhaak RG, Goudswaard CS, van Putten W et al (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747-3754
41. Vishwanatha JK, Chiang Y, Kumble KD et al (1993) Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14:2575-2579
42. Wu MH, Chang JH, Yung BY (2002a) Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis 23:93-100
43. Wu MH, Chang JH, Chou CC, Yung BY (2002b) Involvement of nucleophosmin/B23 in the response of HeLa cells to UV irradiation. Int J Cancer 97:297-305
44. Xu RH, Pelicano H, Zhou Y et al (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613-621
45. Yang YX, Hu HD, Zhang DZ et al (2007) Identification of proteins responsible for the development of adriamycin resistance in human gastric cancer cells using comparative proteomics analysis. J Biochem Mol Biol 40:853-860
46. Yao HX, Zhang ZQ, Xiao ZQ et al (2009) Identification of metastasis associated proteins in human lung squamous. carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 65:41-48
47. Ye KQ (2005) Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. Cancer Biol Ther 4:918-923
48. Yung BY, Busch H, Chan PK (1985) Translocation of nucleolar phosphoprotein B23 (37 kDa/pI 5.1) induced by selective inhibitors of ribosome synthesis. Biochim Biophys Acta 826:167-173
49. Zhang M, Jin S, Zhang M (2009a) Establishing human multi-drug resistant bladder cancer cell lines Pumc-91/ADM and evaluating its biological characteristics. J Med Res 38(1):70-72
50. Zhang Fei, Zhang Lin, Zhang Bin et al (2009b) Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 8:3430-3438